Recently, Alphamab Oncology has secured heavyweight honors in two authoritative selections within China's pharmaceutical industry, highlighting the company's comprehensive strength and leading position in the field of Chinese biological innovative drugs.
At the 17th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (2024 CHSESI), Alphamab Oncology has been granted with "Top 100 Chinese Pharmaceutical Innovative Enterprises" for the seventh time. This ranking is jointly launched by Healthcare Executive and Clarivate Analytics, taking the four indications (the number of authorized patents, total number of patent citations, the number of clinical trials and the number of innovative drugs approved and commercialized) as the basis for evaluation. The selected enterprises represent the "first tier" of China's pharmaceutical innovation capability and are the core force driving industrial upgrading and enhancing global competitiveness. Alphamab Oncology's inclusion in this list for seven consecutive years fully demonstrates its sustained leading advantages in innovative R&D, technology transformation, and industrial implementation.
At the 2025 China Healthcare Decision-makers Conference (2025 CHDC) and the China Innovative Drug Decade Achievement Tour, Alphamab Oncology was listed on the "China Innovative Drug Decade Glory" honor roll and awarded the "Industry-leading Biotech Company". This award is based on complete industrial chain data from PharmaGO and comprehensively assesses aspects such as pipeline competitiveness, clinical and commercial value, internationalization layout, and capital market recognition. It aims to recognize benchmark enterprises that are powered by innovation, committed to addressing unmet medical needs, and demonstrate competitiveness globally. This serves as high recognition for Alphamab Oncology's decade-long dedication to the field of innovative drugs.
Over the years, Alphamab Oncology has independently developed industry-leading, modular, and iterative core technology platforms. The company has built a product pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies, forming a technological moat with differentiated innovation capabilities and international competitiveness.
In 2025, under the strategic vision of “developing differentiated, clinically valuable and globally competitive new drugs”, the company has achieved positive progress across its core product pipeline: The Phase III clinical study of Anbenitamab (KN026) achieved excellent efficacy in second-line or third-line HER2-positive gastric cancer, met both its primary endpoints of progression-free survival (PFS) and overall survival (OS) with statistically significant and clinically meaningful improvements, indicating its potential to change clinical practice guidelines for the treatment of second-line or above gastric cancer. The registrational clinical studies for JSKN003, including HER2-positive breast cancer, all-comer platinum-resistant ovarian cancer, HER2-low breast cancer, and HER2-positive colorectal cancer, are advancing rapidly. JSKN003 has been granted designations including Breakthrough Therapy, Orphan Drug, and Fast Track by both Chinese and U.S. regulatory authorities, with the first New Drug Application (NDA) expected to be submitted in 2026. JSKN016 has demonstrated promising efficacy across multiple solid tumors and a favorable safety profile with low hematological toxicity and is poised to advance into Phase III clinical studies. JSKN022, the world's first PD-L1/αvβ6 bispecific ADC to enter clinical studies, is expected to offer new treatment options for more cancer patients.
Looking ahead, Alphamab Oncology will continue to deepen technological iteration and source innovation, accelerating the clinical translation and global expansion of its innovative pipeline, primarily the next generation of ADC therapeutics.
About Alphamab Oncology
Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK).
Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
